Jacobs Levy Equity Management Inc. Purchases 92,468 Shares of Metagenomi, Inc. (NASDAQ:MGX)

Jacobs Levy Equity Management Inc. boosted its position in shares of Metagenomi, Inc. (NASDAQ:MGX) by 209.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 136,624 shares of the company’s stock after purchasing an additional 92,468 shares during the period. Jacobs Levy Equity Management Inc. owned about 0.37% of Metagenomi worth $296,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in MGX. Rhumbline Advisers bought a new position in Metagenomi during the 2nd quarter worth about $26,000. BNP Paribas Financial Markets boosted its stake in shares of Metagenomi by 130.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 12,799 shares of the company’s stock worth $28,000 after buying an additional 7,256 shares during the last quarter. XTX Topco Ltd acquired a new position in shares of Metagenomi during the 2nd quarter worth about $66,000. Green Alpha Advisors LLC acquired a new position in shares of Metagenomi during the 3rd quarter worth about $69,000. Finally, Verition Fund Management LLC acquired a new position in shares of Metagenomi during the 3rd quarter worth about $82,000.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on MGX shares. Chardan Capital restated a “buy” rating and set a $15.00 price objective on shares of Metagenomi in a research note on Wednesday, November 20th. HC Wainwright increased their price objective on shares of Metagenomi from $7.00 to $14.00 and gave the stock a “buy” rating in a research note on Tuesday. Finally, BMO Capital Markets reduced their price objective on shares of Metagenomi from $22.00 to $17.00 and set an “outperform” rating for the company in a research note on Thursday, August 15th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, Metagenomi currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.67.

Metagenomi Stock Up 0.5 %

MGX stock opened at $4.19 on Wednesday. Metagenomi, Inc. has a one year low of $1.61 and a one year high of $12.74. The company has a fifty day moving average price of $2.06 and a two-hundred day moving average price of $3.29.

Metagenomi Company Profile

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.